Reviving antibiotics
for better benefits
Nanoreviv
NanoReviv is specializing in reformulation of existing molecules to give them a second life. Thus, by improving their PK/PD characteristics thanks to their vectorization in lipid nanocapsules.
Bacterial resistance kills thousands of patients every year
This threat imposes us to find new antibiotics or alternatives. Nanomedicines is one of these options, particularly using nano-vectors to deliver antibiotics in infection sites selectively with respecting microbiota and the environment. That is the way we have chosen to participate in the battle against bacterial resistance.
NanoReviv developed a proprietary nanotechnology to improve the prevention and treatment of various local infections.
Our company has achieved a breakthrough in medicine by developing a unique treatment that can be applied locally, once, precisely when, where, and as needed, revolutionizing the way healthcare is provided. Our complementary team is composed of experts in medical microbiology, nano-development & formulation, and infectiologists.
Thermosetting gel containing lipid nanocapsules
EASE OF MANUFACTURING
Known antibiotics
& approved
excipients
STAPH-EX
NanoReviv' drug-delivery technology consists in lipid nanocapsules (LNC) dispersed in a thermosetting gel; both the LNC and the gel contain antibiotics ensuring both immediate and sustained release of the drug lasting over at least two weeks.'
The formulation is available as a ready-to-use syringe which forms a gel upon administration in an infection site. The drugs are then delivered at a controlled rate, leading to sustained high local concentrations of antibiotics for increased efficacy. The platform can be applied to a variety of antibiotics and in different indications where local delivery is desirable, including, for example, ear infections, skin infections, prevention of implant or prosthesis infections, osteomyelitis etc.
Our first product – called Staph-EX – is currently in pre-clinical development. Staph-EX contains daptomycin and is aimed at Bone & Joint Infections (BJI). A PCT was filed in 2019 and the European Patent was published in 2020 (EP3908265). Applications were filed in 2021/2022 in USA, Canada, China, Hong Kong, and Israel. A Freedom to Operate search has been conducted (USA, 2021).
